Skip to main content

Table 3 ANOVA (Analysis of variance) for study of main effects, two-way interactions and quadratic effects of high-risk CPVs (Critical Procedure Variables) on selected critical responses R1 and R2 using central composite design and MINITAB 18 software

From: Method operable design region for robust RP-HPLC analysis of pioglitazone hydrochloride and teneligliptin hydrobromide hydrate: incorporating hybrid principles of white analytical chemistry and design of experiments

Source

Degree of freedom

Adjusted SS

Adjusted MS

F-Value

P-Value

Level of significance

ANOVA for Response – R1

Model

5

52.3728

10.4746

34.18

0.000

Significant

 Linear

2

48.5472

24.2736

79.21

0.000

Significant

  CPV—A

1

48.4942

48.4942

158.24

0.000

Significant

  CPV—B

1

0.0530

0.0530

0.17

0.690

Non-significant

 Square

2

3.8225

1.9113

6.24

0.028

Significant

  CPV—A*CPV—A

1

3.6088

3.6088

11.78

0.011

Significant

  CPV—B*CPV—B

1

0.4987

0.4987

1.63

0.243

Non-significant

 2-Way Interaction

1

0.0030

0.0030

0.01

0.924

Non-significant

  CPV—A*CPV—B

1

0.0030

0.0030

0.01

0.924

Non-significant

ANOVA for Response – R2

Model

5

3.15345

0.63069

53.55

0.000

Significant

 Linear

2

1.69232

0.84616

71.84

0.000

Significant

  CPV—A

1

0.00000

0.00000

0.00

0.994

Non-significant

  CPV—B

1

1.69232

1.69232

143.69

0.000

Significant

 Square

2

1.46112

0.73056

62.03

0.000

Significant

  CPV—A*CPV—A

1

0.01973

0.01973

1.67

0.237

Non-significant

  CPV—B*CPV—B

1

1.46082

1.46082

124.03

0.000

Significant

 2-Way Interaction

1

0.00000

0.00000

0.00

1.000

Non-significant

  CPV—A*CPV—B

1

0.00000

0.00000

0.00

1.000

Non-significant